Brahman Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Brahman Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,303,003	Closed	-$16.1M	–	24
2020 Q2	$16.1M	Sell	1,303,003 -99,119	-7%	-$1.12M	1.55%	21
2020 Q1	$12.6M	Sell	1,402,122 -557,878	-28%	-$5.72M	1.48%	13
2019 Q4	$19.2M	Buy	+1,960,000	New	+$17.5M	1.84%	14
2019 Q2	–	Sell	-7,064,540	Closed	-$111M	–	15
2019 Q1	$111M	Sell	7,064,540 -5,183,566	-42%	-$91.4M	7.84%	6
2018 Q4	$189M	Buy	12,248,106 +4,925,245	+67%	+$101M	10.92%	5
2018 Q3	$158M	Sell	7,322,861 -3,274,818	-31%	-$76M	7.89%	6
2018 Q2	$258M	Sell	10,597,679 -1,694,721	-14%	-$34.6M	12.19%	2
2018 Q1	$210M	Buy	12,292,400 +2,346,888	+24%	+$45.8M	8.82%	5
2017 Q4	$188M	Buy	+9,945,512	New	+$150M	7.13%	7

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Brahman Capital's TEVA Position: Q3 2020 in Review

Brahman Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2020, closing a stake of 1,303,003 shares — an estimated $16.1M sold.

Brahman Capital first reported a position in TEVA in Q4 2017 and held it in 9 quarters. The position peaked at $258M in Q2 2018. 443 funds tracked by Wall St. Rank hold TEVA as of Q3 2020.

Brahman Capital reported no remaining Teva Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Brahman Capital sold 1,303,003 Teva Pharmaceuticals shares in Q3 2020, an estimated $16.1M.
Brahman Capital first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Brahman Capital's Teva Pharmaceuticals position peaked at $258M in Q2 2018.
443 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2020.

Based on Brahman Capital's 13F filing for Q3 2020, filed 16 Nov 2020.